Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the J.P....
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Offering includes Animal Origin-Free Preps, Transfection-Grade Preps and Target Yield with turnaround time starting at four business days for Express Genes Enables nucleic acids therapeutics research,...
Twist Bioscience: Fiscal Q4 Earnings Snapshot
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025...
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist,...
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that it...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Company to host conference call at 8:00 AM ET
In a report released today, Luke Sergott from Barclays maintained a Buy rating on Twist Bioscience, with a price target of $40.00. The company’s shares closed yesterday at $32.04.Elevate Your Investing...